Journal of
Cancer Research and Experimental Oncology

  • Abbreviation: J. Cancer Res. Exp. Oncol.
  • Language: English
  • ISSN: 2141-2243
  • DOI: 10.5897/JCREO
  • Start Year: 2009
  • Published Articles: 53

Full Length Research Paper

Oncogenic human papillomavirus (HPV) in women from Ghana

Brandful J. A. M.*
  • Brandful J. A. M.*
  • Department of Virology, Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences (CHS), University of Ghana, Legon, Accra, Ghana.
  • Google Scholar
Bonney E.Y.
  • Bonney E.Y.
  • Department of Virology, Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences (CHS), University of Ghana, Legon, Accra, Ghana.
  • Google Scholar
Asmah R. H.
  • Asmah R. H.
  • Department of Medical Laboratory Sciences, School of Allied Health Sciences, CHS University of Ghana, Ghana.
  • Google Scholar
Apea-Kubi K. A.
  • Apea-Kubi K. A.
  • Department of Obstetric and Gynaecology, KorleBu Teaching Hospital, Accra, Ghana.
  • Google Scholar


  •  Received: 16 July 2014
  •  Accepted: 15 December 2014
  •  Published: 31 December 2014

References

Adanu RG (2012). Personal communication.
 
Attoh S, Asmah R, Wiredu, EK, Gyasi R, Tettey Y (2010). Human Papilloma virus genotypes in Ghanaian women with cervical carcinoma, East Africa Med. J. 87(8):345-347.
Pubmed
 
Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky D, Barr E (2004). Phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22 (23-24):3004-3007.
Crossref
 
Bosch FX, de Sanjose S (2003). Human papilloma virus and cervical cancer-burden and assessment of causality. J. Natl. Cancer Inst. Monogr. 31:3-13.
Crossref
 
Bosch FX, Qiao YL, Castellsagué X (2006). The epidemiology of human papillomavirus infection and its association with cervical cancer. Intl. J. Gynecol. Obst. 94:8-21.
Crossref
 
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009). A review of human carcinogens-Part B: Biological Agents Lancet Oncol. 10:321-322.
Crossref
 
Castle PE, Solomon D, Schiffman M, Wheeler CM (2005). Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl. Cancer Inst. 97(14):1066-1071.
Crossref
 
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F (2005). Carcinogenicity of human papillomaviruses. WHO International Agency for Research on Cancer. Lancet Oncol. 6(4):204.
Crossref
 
Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Vallès X, Ouedraogo A, Konate I, Weiss HA, Van de Perre P, Mayaud P, Segondy M (2006). Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br. J. Cancer 7:95(3):355-362.
 
Erickson BK, Alvarez, RD, Huh WK (2013). Human Papillomarvirus: What Every Provider Should Know. Am. J. Obst. Gynecol. 14:1-7.
 
Ghana Health Service (GHS) (2013). Ministry of Health Press release, Ghana.
 
Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; (2002). Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347(21):1645-1651.
Crossref
 
Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ (1992). Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79(3):328-337.
Crossref
 
Mu-oz N, Bosch X, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJL (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
Crossref
 
Mu-oz N, Méndez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Mu-oz A, Instituto Nacional de Cancerologia HPV Study Group (2004). Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis. 190(12):2077-2087.
Crossref
 
Parkin DM, Pisani P, Ferlay J (1999). Global cancer statistics. CA Cancer J. Clin. 49(1):33-64.
Crossref
 
Schiffman M, Castle PE (2005). The promise of global cervical-cancer prevention. N. Engl. J. Med. 353:2101-2104.
Crossref
 
Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD (2005). The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337(1):76-84.
Crossref
 
Schiffman M, Kruger-Kjær S (2003). Natural history of anogenital human papillomavirus infection and neoplasia. J. Natl. Cancer Inst. Monogr. 31:14-19.
Crossref
 
Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Franco EL (2003). Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 95(17):1336-1343.
Crossref
 
Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Menton S, Menton M, Dietz K, Wallweiner D, Kandolf R, Bultmann B (2004). Detection and typing of human papillomavirus by E6 nested multiplex PCR. J. Clin. Micobiol. 42:3176-3184.
Crossref
 
Trottier H, Mahmud S, Duarte-Franco E, Villa LL, Costa MC, Sobrinho JP Rohan TE, Ferenczy A, Franco EL (2006). Human Papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 15(7):1274-1280.
Crossref
 
Valles X, Murga GB, Hernandez G, Sabid M, Chuy A, Alameda F, San Jose S-D, Bosch FX, Pedrosa I, Castelle S, Casabona J (2009). High prevalence of human papillomavirus infection in the female population of Guatemala. Int. J. Cancer 125:1161-1167.
Crossref
 
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson S-E, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6(5):271-278.
Crossref
 
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Mu-oz N (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1):12-19.
Crossref
 
Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE (2009). Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J. Natl. Cancer Inst. 101(7):475-487.
Crossref
 
Zur Hausen H (2000). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92(9):690-698.
Crossref